RxDoctor Payments DataLook up a doctor →

Mark Skeen, MD

Neurology · Durham, NCNPI 1497839351

Payments from drug & device makers

$561,616in general payments, 2019–2025

Across 537 payments — averaging $1045.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$161K
  • AstraZeneca$134K
  • EMD Serono, Inc.$64K
  • Novartis$55K
  • E.r. Squibb & Sons, L.L.C.$54K
  • Bristol Myers Squibb$39K
  • plus $54K from 7 others
$25in research payments, 2019–2025

Across 1 payment — averaging $25.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$25

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$561,616 in reported general payments places this provider in the 90th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$25,413
Medicare patients
128
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →